Agilent Technologies (A) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
6 Feb, 2026Executive summary
Annual meeting scheduled for March 18, 2026, with four director elections, advisory vote on executive compensation, auditor ratification, and a proposal to declassify the Board over three years.
Board recommends voting for all proposals, citing alignment with long-term strategy, governance best practices, and shareholder feedback.
Forward-looking statements are included, with risks detailed in the Annual Report.
Voting matters and shareholder proposals
Four directors nominated for three-year terms: Judy Gawlik Brown, Sue H. Rataj, George A. Scangos, Ph.D., and Dow R. Wilson.
Advisory vote on executive compensation, with Board recommending approval based on pay-for-performance alignment.
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026.
Proposal to declassify the Board, transitioning to annual elections by 2029, following strong shareholder support.
Board of directors and corporate governance
Ten of eleven directors are independent; Board has a mix of skills, experience, and tenure.
Independent Chairperson, regular executive sessions, annual self-assessments, and majority voting policy.
Proxy access for shareholders and robust stock ownership guidelines for directors.
Board refreshment ongoing, with four new independent directors in the past five years.
Latest events from Agilent Technologies
- Q1 FY26 revenue rose 7% to $1.80B, non-GAAP EPS up 4%, and FY26 guidance was raised.A
Q1 20263 Mar 2026 - Strong growth, innovation, and disciplined strategy support positive outlook for the year.A
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Key votes include director elections, auditor ratification, and Board declassification.A
Proxy Filing6 Feb 2026 - Q2 met expectations, but slower recovery and China headwinds led to a guidance cut.A
Jefferies Global Healthcare Conference31 Jan 2026 - Annual meeting to elect directors, approve pay, ratify auditor, and declassify the Board.A
Proxy Filing23 Jan 2026 - Q3 revenue beat guidance, net income surged, and full-year outlook was raised amid market challenges.A
Q3 202423 Jan 2026 - FY26 targets 4–6% core growth, margin gains, and $7.3B–$7.4B revenue via Ignite and innovation.A
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Q4 non-GAAP EPS up 6% to $1.46; FY25 revenue and EPS growth expected.A
Q4 202412 Jan 2026 - Ignite strategy drives 5%-7% growth, margin expansion, and leadership in high-growth markets.A
Investor Day 202411 Jan 2026